Antibiotic therapy of community respiratory tract infections: Strategies for optimal outcomes and minimized resistance emergence

Journal of Antimicrobial Chemotherapy

Volumn 49, Issue 1, 2002, Pages 31-40

  Ball, P ^a,j   Baquero, F ^c   Cars, O ^e   File, T ^f   Garau, J ^d   Klugman, K ^g   Low, D E ^h   Rubinstein, E ⁱ   Wise, R ^b  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL MÚTUA DE TERRASSA   (Spain)

^e UPPSALA UNIVERSITY   (Sweden)

^f SUMMA HEALTH SYSTEM   (United States)

^g EMORY UNIVERSITY   (United States)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ SHEBA MEDICAL CENTER   (Israel)

^j NONE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; CHRONIC BRONCHITIS; CLINICAL PRACTICE; COMMUNITY; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG CHOICE; DRUG COST; DRUG EFFICACY; HOSPITAL ADMISSION; HUMAN; MORBIDITY; NONHUMAN; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE;

EID: 0036151585     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/49.1.31     Document Type: Review

References (115)

1. Acute respiratory infections: The forgotten pandemic
2. Prevention of pneumococcal disease: Recommendations of the advisory committee on immunization practices (ACIP)
3. Emergence of drug-resistant pneumococcal infections in the United States
4. The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
5. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
6. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
7. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999)
8. Antibiotic prescribing and antibiotic resistance in community practice: Retrospective study, 1996-8
9. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance
10. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe
11. Minimising the impact of drug-resistant Streptococcus pneumoniae (DRSP): A strategy from the DRSP working group
12. Pressures on the general practitioner and decisions to prescribe
13. Influence of patients' expectations on antibiotic management of acute lower respiratory tract illness in general practice: Questionnaire study
14. Continued decline in the incidence of penicillin non-susceptible pneumococci in Iceland
15. Role of communicable disease control measures in affecting the spread of resistant pneumococci: The Swedish model
16. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland
17. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction
18. American Thoracic Society guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
19. Community-acquired pneumonia in adults: Guidelines for management
20. Community-acquired pneumonia guidelines - An international comparison: A view from Europe
21. Guidelines for management of adult community-acquired lower respiratory tract infections
22. Guidelines for the management of community acquired pneumonia in adults admitted to hospital
23. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia
24. Why don't physicians follow clinical practice guidelines? A framework for improvement
25. Consider short courses of antibiotics
26. Performance failure of an evidence-based upper respiratory infection clinical guideline
27. Pharmacoeconomic studies on antibiotics: Current controversies
28. Antibiotic prescribing for Canadian preschool children: Evidence of overprescribing for viral respiratory infections
29. Assessment of antibiotic prescription in acute respiratory infections in adults
30. Trends in antimicrobial drug prescribing among office-based physicians in the United States
31. Antibiotic prescribing for adults with colds, upper respiratory tract infection, and bronchitis by ambulatory care physicians
32. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: A fifteen year experience at the University of Virginia and review of selected studies
33. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis
34. Otitis media - Principles of judicious use of antimicrobial agents
35. A roundtable discussion of antibiotic resistance: Putting the lessons to work
36. Randomised placebo-controlled trials of antibiotics for acute bronchitis: A critical review of the literature
37. Acute exacerbations of chronic bronchitis: An international comparison
38. Efficacy of pneumococcal vaccination in adults: A meta-analysis of randomised controlled trials
39. Prophylaxis and treatment of influenza
40. The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community
41. Effects of a large scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: A prospective study
42. Evidence to support the rationale that bacterial eradication in respiratory tract infection provides guidance for antimicrobial therapy
43. Measuring the comparative efficacy of antibacterial agents for acute otitis media: The 'Polyanna phenomenon'
44. Modeling and predicting clinical outcomes of antibiotic therapy
45. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis
46. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae
47. Gemifloxacin long-term exacerbations in bronchitis exacerbations (GLOBE) study - An assessment of health outcome benefits in AECB patients following 5 days of gemifloxacin therapy
48. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections
49. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
50. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
51. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections
52. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
53. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
54. Antibiotic dosing issues in lower respiratory tract infection: Population-derived area under inhibitory curve is predictive of efficacy
55. AUIC - The universal parameter within the constraint of a reasonable dosing interval
56. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
57. Application of fluoroquinolone pharmacodynamics
58. Pharmacodynamics to combat resistance
59. Antibiotic clinical trials - The Witley Park Symposium
60. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae
61. In vivo efficacies of amoxicillin and cefuroxime against penicillin-resistant Streptococcus pneumoniae in a gerbil model of acute otitis media
62. Comparative efficacy of gemifloxacin (SB-265805) against experimental respiratory tract infection in rats caused by ciprofloxacin-resistant strains of Streptococcus pneumoniae and Haemophilus influenzae
63. Bacteriologic response in acute otitis media: Comparison between azithromycin, cefaclor and amoxicillin
64. The bacteriologic efficacy of 1-day versus 3-day intramuscular ceftriaxone (IMN-CRO) in the treatment of non-responsive acute otitis media (NR-AOM)
65. Management of community-acquired pneumonia in the era of pneumococcal resistance
66. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain
67. Antibiotic-resistant pneumococcal disease in South African children
68. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
69. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci
70. A seventeen-year epidemiological survey of antimicrobial resistance in pneumococci in two hospitals
71. Therapy for pneumococcal infection at the millennium: Doubts and certainties
72. Penicillin-resistant pneumococci and community acquired pneumonia
73. Clinical failures: The tip of the iceberg?
74. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin or clarithromycin monotherapy
75. Bacteremic pneumonia due to pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin
76. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy
77. Macrolide resistant Streptococcus pneumoniae and use of antimicrobial agents
78. Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae
79. Levofloxacin treatment failures of pneumococcal pneumonia in association with resistance
80. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection
81. Low dosage and long treatment duration of β-lactam. Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae
82. Trends in antibiotic resistance of respiratory pathogens: An analysis and commentary on a collaborative surveillance study
83. In vitro activities of oral β-lactams at concentrations achieved in humans against penicillin-susceptible and -resistant pneumococci and potential to select resistance
84. Evolving resistance patterns of S. pneumoniae: A link with long-acting macrolides?
85. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae
86. Strategies to minimize the development of antibiotic resistance
87. Mechanisms of quinolone resistance
88. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: Comparison with ciprofloxacin, sparfloxacin and ofloxacin
89. A multicenter, randomised study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community acquired pneumonia
90. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalised patients with pneumonia
91. Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mild-to-moderate community-acquired pneumonia
92. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral and intravenous doses
93. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case-control study
94. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study
95. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella
96. Evaluating treatment protocols to prevent antibiotic resistance
97. The population genetics of antibiotic resistance
98. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli
99. The biological cost of antibiotic resistance
100. A global gene pool for high level cephalosporins resistance in commensal Streptococcus species and Streptococcus pneumoniae
101. How do we achieve cost-effective options in lower respiratory tract infection therapy?
102. A controlled trial of a critical pathway for treatment of community-acquired pneumonia
103. Effect of new guidelines and a respiratory quinolone on clinical outcomes in hospitalised patients with community-acquired pneumonia
104. Assessing the cost implications of microbiological sensitivity results to antibiotic treatment in lower respiratory tract infections (LRTI)
105. Economic evaluation of alternative antibiotic regimens in the management of acute exacerbations of chronic bronchitis
106. Cost benefits from improving clinical outcome
107. Burden and cost of LRTI: A methodologic overview
108. Cost of communityacquired lower respiratory tract (LRTI) in an HMO
109. Treatment cost of acute exacerbations of chronic bronchitis
110. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbation of chronic bronchitis
111. Cost-effectiveness of gemifloxacin versus clarithromycin in the treatment of AECB; the Globe study
112. Variation in antibiotic use in the European Union
113. Development of practice guidelines
114. The effects of clinical practice guidelines on patient outcomes in primary care: A systematic review